This inventor holds 1 USPTO granted patent. Top assignee: Xi'an Xintong Pharmaceutical Research Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Junjie Wang and His Patent on Kinase Inhibitors.
Introduction
Junjie Wang is an inventor associated with Xi’an, China, and Xi’an Xintong Pharmaceutical Research Co., Ltd. His disclosed work concerns compounds investigated for their potential to inhibit BTK and JAK3 kinases.
Latest Patents
Wang is associated with 1 patent: “Substituted benzo[d][1,3]dioxoles as BTK and/or JAK3 kinase inhibitors.” The patent describes a 1,3-benzodioxol derivative of general formula (I). Reported pharmacological experiments indicate that the compound can inhibit both BTK and JAK3 kinases. The disclosure proposes using the compound to prepare medicines for rheumatoid arthritis associated with overactivation of BTK and/or JAK3 pathways, and also describes a method for preparing the derivative.
Career Highlights
The available information connects Wang’s patent work with Xi’an Xintong Pharmaceutical Research Co., Ltd. His disclosed invention focuses on kinase inhibition and a potential pharmaceutical application in rheumatoid arthritis.
Collaborations
Yungen Xu and Tingting Liang are identified as Wang’s coworkers.
Conclusion
Junjie Wang’s disclosed patent centers on a 1,3-benzodioxol compound designed to inhibit BTK and JAK3 kinases, with a proposed application in rheumatoid arthritis treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile